Chitosan hydrogel containing tacrolimus-loaded nanoliposome for ocular drug delivery: Physicochemical analysis and stability evaluation

被引:0
作者
Hassansheikhi, Parisa [1 ]
Ameri, Elham [2 ]
Alimohammadi, Zahra [1 ]
机构
[1] Islamic Azad Univ, Dept Chem Engn, Shahreza Branch, Shahreza, Iran
[2] Islamic Azad Univ, Dept Chem Engn, Najafabad Branch, Najafabad, Iran
关键词
Tacrolimus; Nanoparticles; Ophthalmic; Chitosan; Hydrogel; IN-VIVO; HYALURONIC-ACID; NANOPARTICLES; RELEASE; CYCLOSPORINE; SYSTEMS; PHARMACOKINETICS; STRATEGIES; RETENTION; LIPOSOMES;
D O I
10.22038/nmj.2024.80007.1977
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Objective(s): Recently, the use of tacrolimus in treating eye diseases has received much attention. Although this drug is powerful in treating eye diseases, however for various reasons, it lacks the necessary efficacy for multiple reasons. This research investigated the development of Tacrolimus encapsulated liposomes, optimization, loading effectiveness, increasing drug efficiency through absorption, controlled release, drug targeting, and reducing drug side effects such as nephropathy. Materials and Methods: Two agents, liposome and chitosan, have been chosen to transport the drugs used in this study. Nanoliposomes were synthesized through the heating method and chitosan nanoparticles were by reversing the micelle method. A field emission scanning electron microscope(FESEM) was used to prepare images and a zeta sizer was used to measure the average size and distribution of particles. Drug release for 18 days was checked by in vitro and ex-vivo(Franz diffusion) tests. The MTT method was used to evaluate the cytotoxic effect of nanoparticles loaded with tacrolimus drug. Results: The molar ratio of the drug to liposome and chitosan was chosen to be 0.002. A drug loading effectiveness of (88-95%) was obtained. Tacrolimus drug loading efficiency in liposomes (EPC100, EPC80, DPPC60, DPPC100) value (88.95-95-74%) was obtained for its entrapment in liposome core with passive loading strategy. The difference in drug release rate for EPC 80/chitosan liposome and EPC 100/chitosan was 83.6% and 93.1%, respectively, and for DPPC60/chitosan and DPPC100/chitosan liposomes, 72.8% and 78.8%, respectively. Conclusion: With this study, it can be concluded that DPPC liposome was good for drug loading. The results of the test (FT-IR) showed that the loading of the drug was successful. The results of electron microscope tests in both samples (EPC, DPPC) indicated the synthesis of drug delivery systems with a spherical morphology with a diameter of less than 100 nanometers. The release results showed that the highest release rate was related to EPC liposomes. In the MTT test, it was observed that nanocarriers without tacrolimus drugs do not show any toxic effect on cells.
引用
收藏
页码:299 / 312
页数:14
相关论文
共 65 条
[1]  
Amardeep A., 2012, IOSR J PHARM, V2, P317, DOI [10.9790/3013-0220317321, DOI 10.9790/3013-0220317321, 10.1016/j.ijpharm.2017.07.036, DOI 10.1016/J.IJPHARM.2017.07.036]
[2]  
Babu R, 2015, Modification of the Stratum Corneum Springer, P133
[3]   Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles [J].
Banerjee, T ;
Mitra, S ;
Singh, AK ;
Sharma, RK ;
Maitra, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 243 (1-2) :93-105
[4]   PharmGKB summary: cyclosporine and tacrolimus pathways [J].
Barbarino, Julia M. ;
Staatz, Christine E. ;
Venkataramanan, Raman ;
Klein, Teri E. ;
Altman, Russ B. .
PHARMACOGENETICS AND GENOMICS, 2013, 23 (10) :563-585
[5]   Controlled release of β-estradiol from PLAGA microparticles:: The effect of organic phase solvent on encapsulation and release [J].
Birnbaum, DT ;
Kosmala, JD ;
Henthorn, DB ;
Brannon-Peppas, L .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (03) :375-387
[6]   Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases [J].
Bisht, Rohit ;
Mandal, Abhirup ;
Jaiswal, Jagdish K. ;
Rupenthal, Ilva D. .
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2018, 10 (02)
[7]  
Bochot A, 2002, INVEST OPHTH VIS SCI, V43, P253
[8]  
Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO
[9]  
2-4
[10]  
Camargo GD, 2021, RSC Pharm, V13, P2013